Skip to main content
Premium Trial:

Request an Annual Quote

Microbial Genetics Analysis Company OpGen Receives CLIA Accreditation

NEW YORK (GenomeWeb News) – Microbioal genetic analysis firm OpGen today announced it has received Clinical Laboratory Improvement Amendments certification.

As a result, the Gaithersburg, Md.-based firm is launching its clinical services lab focused on developing genetic tests and analysis services for surveilling and identifying healthcare-associated infections and human pathogens.

OpGen's clinical services lab uses next-generation DNA and genetic analysis technology, including multiplex real-time PCR, whole genome mapping, and next-generation sequencing. As a result, it can offer low cost genetic testing for the screening, surveillance, diagnosis, gene content, and epidemiological analysis of infectious diseases, it said.

It offers whole genome mapping genetic analysis of HAIs, and sequence analysis of C. difficile on a worldwide basis, and it will offer real-time PCR screening and surveillance of MRSA and complete C. difficile hypervirulence diagnostic testing services in the mid-Atlantic region.

Additionally, OpGen is developing tests for gram-negative and gram-positive multidrug resistant organisms, it said.

"OpGen is building on the success of our whole genome mapping applications in the public health and life sciences sectors to expand our capabilities to help hospitals and healthcare facilities combat HAIs and complex human pathogens, OpGen CEO Douglas White said in a statement. "With the opening of our CLIA-certified laboratory, OpGen will provide a unique, comprehensive offering of infectious disease screening, diagnostic, and epidemiology services."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.